InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,796.00
(
0.60%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
-0.63%
)
Bitcoin
57,793.42
(
0.77%
)
Post# of 252586
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: linhdtu post# 214555

Tuesday, 10/24/2017 1:47:18 PM

Tuesday, October 24, 2017 1:47:18 PM

Post# of 252586
GILD has NASH candidates with a few different MoAs. For FXR agonists, specifically, GILD's GS-9674 is ahead of ENTA's EDP-305, having started phase-2 for NASH in Oct 2016 (https://www.clinicaltrials.gov/ct2/show/NCT02854605 ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up